rais target ahead
data potenti blockbust tafamidi come soon
present data rare diseas asset tafamidi treatment
transthyretin cardiomyopathi attr-cm alreadi announc top-
line result full data set help defin potenti tafamidi
could first-in-class drug attr-cm preval attr-cm
known theoret market size could well bn
view tafamidi potenti blockbust note provid
color tafamidi team physician expert also ad
preliminari estim tafamidi model updat dcf analysi
reflect discount back end better
approxim one-year target took pt
tafamidi profil flush esc
announc posit top-lin result phase studi attr-act
tafamidi attr-cm
march tafamidi significantli reduc
composit primari endpoint all-caus mortal frequenc cv-relat
hospit vs placebo month studi first outcom
data attr-cm believ could year ahead other
outcom data popul full data present
european societi cardiolog esc meet
attr-cm rare diseas high mortal approv treatment
attr multi-system diseas misfold ttr protein caus
amyloid fibril accumul nerv heart tissu interf
normal function attr-cm amyloid deposit heart lead
progress heart failur estim diagnos
us repres peopl diseas averag life
expect year diagnosi approv drug
sound confid tafamidi data
background abl speak dr brenda cooperston
pfe chief develop offic diseas dr cooperston note
esc present includ data compon primari
endpoint all-caus mortal cv-relat hospit result
secondari endpoint data stratifi wild-typ vs hereditari form
diseas result dosag view compani
sound quit confid robust result
perspect tafamidi physician expert
spoke academ cardiologist experi treat attr-cm
familiar tafamidi agent develop similar
doc believ attr-cm under-diagnos like
preval caus heart failur tafamidi would view improv
all-caus mortal efficaci wild-typ mutant patient efficaci
secondari endpoint home run would prescrib tafamidi even
modest data given lack treatment option
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar firm may conflict interest could affect object report investor
consid report singl factor make invest decis disclosur analyst
price aug usd
valuat risk
pt base dcf wacc
impli stock trade
ep downsid risk
includ lower-than-expect sale
key product greater price pressur
us europ area pipelin
failur disappoint capit
like strong financi posit attract valuat dividend yield
manag team commit sharehold return expect
compani continu leverag strong balanc sheet cash flow
gener sharehold valu also view pipelin success potenti
upsid driver stock buy
target price base dcf analysi model sale
period determin termin valu base termin growth rate
assum termin growth given challeng forecast long-term cash
flow pharmaceut industri discount after-tax profit back
end believ approxim compani weight
averag cost capit target impli stock trade roughli
ep
downsid risk includ lower-than-expect sale key product
earlier-than-expect gener competit key product greater price
pressur us europ area pipelin failur
sound confid tafamidi data
background tafamidi attr-cm abl speak
dr brenda cooperston pfe chief develop offic diseas dr
cooperston provid background diseas condit walk
type data present esc among thing
view compani sound quit confid robust result
highlight tidbit interest discuss
present esc detail includ data
compon primari endpoint all-caus mortal
cv-relat hospit result secondari endpoint data
stratifi wild-typ vs hereditari form diseas result
dosag plan host call investor
analyst follow esc present
preval attr-cm known estim
patient diagnos us
repres peopl condit compani believ
grow diseas awar go long way toward increas
rate diagnosi physician educ ensur avail
nuclear imag facilit diagnosi import
expect file fda approv year-end note
breakthrough therapi design allow compani submit
compon applic differ time character
fda highli engag tafamidi compani also plan
discuss file timelin eu base attr-act data
describ specif potenti timelin
perspect tafamidi physician expert
get expert perspect tafamidi spoke academ
cardiologist signific experi treat patient ttr
amyloidosi familiar tafamidi agent develop
highlight tidbit interest discuss
doc note wild-typ attr-cm probabl quit preval
wild-typ patient tend cardiac involv increas
age believ attr-cm like preval caus
note composit endpoint all-caus mortal cv-
relat hospit tafamidi met phase
challeng endpoint colleagu suspect
benefit driven improv hospit consid
size studi high bar all-caus mortal note
tafamidi show signific benefit all-caus mortal
would big deal
doc would view home run outcom improv all-caus
mortal efficaci wild-typ mutant patient efficaci
secondari endpoint especi walk test
signific improv all-caus mortal modest
improv cv-relat hospit would still prescrib
tafamidi given lack treatment option
within practic sever dozen patient ttr
cardiomyopathi includ mutant wild-typ would treat
tafamidi drug avail plan screen
patient ttr cardiomyopathi via cardiac imag
regard alnylam patisiran ioniss inotersen figur
note tafamidi studi differ patient popul
symptomat cardiomyopathi view drug
competitor liken tafamidi studi alnylam
revusiran endeavour fail due imbal
figur product candid attr
mutant wt phase complet
approv us
file eu approv expect
septemb
approv eu
file us pdufa
phase attr-act studi demonstr signific reduct
composit endpoint all-caus mortal frequenc cv-relat
hospit vs placebo month data present
european societi cardiolog esc meet
plan file fda approv year-end
approv transthyretin famili amyloid polyneuropathi ttr-fap
outsid us
rna interfer drug reduc ttr product liver
approv us treatment polyneuropathi
patient hattr amyloidosi
phase apollo studi demonstr improv cardiac function
base exploratori endpoint data includ label
plan discuss label expans fda could involv
addit studi establish cardiac benefit
commerci onpattro us canada
europ sanofi row commerci right
antisens drug reduc ttr product liver administ
phase neuro-ttr studi demonstr improv neuropathi
qol hattr patient
approv eu treatment polyneuropathi
patient hattr amyloidosi
neuro-ttr demonstr improv cardiac measur patient
signific cardiac diseas includ left ventricl mass
interventricular septum thick posterior wall thick
risk thrombocytopenia glomerulonephr requir monitor
mutant wt phase plan
rna interfer drug reduc ttr product liver
plan initi phase studi hattr amyloidosi late
studi includ certain cardiac paramet endpoint
plan start addit phase studi includ wild-typ
attr amyloidosi
ad preliminari estim tafamidi model
model tafamidi launch sale
difficult gaug market opportun given lack preval data
rare diseas note appli price similar alnylam
onpattro approv polyneuropathi patient
hereditari attr amyloidosi estim diagnos patient
us yield theoret sale assum diagnos patient
repres true preval suggest theoret market size
bn
figur illustr number patient necessari reach sale
differ price point high end alnylam estim net
price onpattro low end impli share number
assum theoret preval patient base pfe
estim patient diagnos repres
figur impli patient patient share base peak sale
price repres alnylam estim net price onpattro
impli share base midpoint theoret market size patient
also model gross margin increment spend
exclus tafamidi cover ip expir
could extend year figur compar new prior
inform expens incom non-controlling incom non-controlling incom changetot inform inform august
inform expens incom non-controlling incom non-controlling incom changetot inform inform august
innov ih intern allianc revenu intern intern allianc pipelineoth immunolog rare rare innov august
essenti eh legaci establish product inject pharmaceut peri-lo peri-lo essenti august
innov ih intern allianc revenu intern intern allianc immunolog rare rare innov august
essenti eh legaci establish product inject pharmaceut peri-lo peri-lo essenti august
